45% Increase in Aktana in Demonstrates Surge in Artificial Intelligence (AI)

Aktana, the leader in intelligent customer engagement for the global life sciences industry, reports new indicators of a shift in artificial intelligence (AI) implementation strategy in commercial life sciences. Notably, Aktana crossed a milestone of 30 million next-best-engagement (NBE) suggestions, including an unprecedented 45% increase in AI-driven omnichannel actions, directly impacting the customer experience of more than 700,000 healthcare professionals in 2021 alone. Leading pharmaceutical companies are now scaling AI capabilities simultaneously across multiple geographies, therapeutic areas and brands rather than taking a market-by-market approach. "Rather than just validating the value of AI, life sciences commercial and medical teams are now realizing the value of AI – in a big way" LEO Pharma, for instance, is expanding use of Aktana's Contextual Intelligence 360 platform across multiple European countries and Canada. "We want to leverage the power of AI to better support healthcare professionals with relevant information when they need it throughout the omnichannel journey," said Marc Tàpies Llobet, senior director, commercial excellence in the EU at LEO. "The rollout of Aktana's solution globally is also key to increase the effectiveness of all our commercial teams with helpful next-best-action suggestions and insights."